log  
logo
A Journal of Postdoctoral Research.
 
     Login   |   Register   
    ISSN : 2328-9791
left right
 
 
Hall of Fame
EDITORIAL BOARD
btm
 
top
  Dr. YIMING ZHONG  
 
Address 1 :
Address 2 :
Title : Dr.
First Name : YIMING
Last Name : ZHONG
University/Institution : Case Western / University Hospitals
Email ID : ymz2036@gmail.com
City : Cleveland
Country : United States
State : Ohio
Zipcode : 44106
Department : Genetics
Company Name :
Area of Research
genetics
Area of Expertise
drug characterization; leukemia and lymphoma; genetics
Brief Description of Research Interest :

Characterize therapeutic agents in leukemiaand lymphoma; investigate the pathogenic mechanisms of leukemia and lymphoma; Genetics Diagnostics.

Representative Publications :

1.      Ta-Ming Liu*, Jennifer A Woyach*, YimingZhong*, Arletta Lozanski,  GerardLozanski, Shuai Dong, Ethan Strattan, Amy Lehman, Xiaoli Zhang, Jeffrey A Jones,Joseph Flynn, Leslie A Andritsos, Kami Maddocks, Samantha M Jaglowski, KristieA Blum, John C Byrd, Jason A Dubovsky, Amy J Johnson.  Hypermorphic mutation of phospholipase C,gamma 2 acquired in ibrutinib resistant CLL confers BTK independency upon BCRactivation. Blood. 2015 Jul 2;126(1):61-8. (Impact factor: 9.775)

 

2.      Zhong Y, Dong S, Strattan E, Ren L, Butchar JP,Thornton K, Mishra A, Porcu P, Bradshaw JM, Bisconte A, Owens TD, Verner E, BrameldKA, Funk JO, Hill RJ, Johnson AJ, Dubovsky JA.  Targeting Interleukin-2-inducible T-cellKinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel CovalentInhibitor PRN694.  The Journal of Biological Chemistry. 2015 Mar 6;290(10):5960-78. (Impact factor: 4.573)

 

3.      Shuai Dong, Daphne Guinn, Jason ADubovsky, Yiming Zhong, Amy Lehman, Jeffery Kutok, Jennifer A Woyach,John C. Byrd, and Amy J Johnson. IPI-145antagonizes intrinsic and extrinsic survival signals in chronic lymphocyticleukemia cells. Blood 2014 Dec 4;124(24):3583-6. (Impact factor: 9.775)

 

4.      Jason A. Dubovsky, Ryan Flynn,Jing Du, Bonnie K. Harrington, YimingZhong, Carrie Yang, Will Towns,Amy Lehman, Amy J. Johnson, Natarajan Muthusamy, Steven Devine, SamanthaJaglowski, Jonathan S. Serody, William J. Murphy,David H. Munn, Leo Luznik,Geoffrey R. Hill, Kelli K.P. MacDonald, Ivan Maillard, John Koreth,Corey Cutler, Robert J. Soiffer,Joseph H. Antin, JeromeRitz, Angela Panoskaltsis-Mortari, John C.Byrd, Bruce R. Blazar.Ibrutinib Treatment Ameliorates Murine Chronic Graft-versus-Host Disease. The Journal of Clinical Investigation 2014 Nov;124(11):4867-76. (Impact factor: 13.765).

 

5.      Ethan Strattan and Yiming Zhong*. Kill the messenger: T-cell/B-cell interactions in cGVHD.  Journal of Postdoctoral Research 2014 2(9): 46-48. (*corresponding author).

 

6.      Dalia El-Gamal, Katie Williams,Taylor LaFollette, Matthew Cannon, James Blachly, Yiming Zhong, JenniferWoyach, Erich Williams, Farrukh Awan, Jeffrey Jones, Leslie Andritsos, KamiMaddocks, Chia-Hsien Wu, Ching-Shih Chen, Amy Lehman, Xiaoli Zhang, RosaLapalombella, and John C Byrd.  PKC-β asa therapeutic target in CLL: PKC Inhibitor AEB071 Demonstrates Pre-clinicalActivity in CLL.  Blood 2014124(9):1481-91 (Impact factor:9.775).

 

7.      Yiming Zhong, Dalia El-Gamal, Jason Dubovsky,Kyle Beckwith, Bonnie Harrington, Katie Williams, Virginia Goettl, ShrutiJha, Xiaokui Mo, Jeffrey Jones, Joseph Flynn, Kami Maddocks, Leslie Andritsos, Dilara McCauley, SharonShacham, Michael Kauffman, John Byrd, andRosa Lapalombella. Selinexor suppresses Downstream Effectorsof B-cell activation, proliferation and migration in chronic lymphocytic leukemiacells. Leukemia 2014 28(5):1158-63 (Impact factor: 10.164)

 

8.      Yiming Zhong, John C.Byrd, Jason A. Dubovsky. The B-cell ReceptorPathway: A Critical Component of Healthy and MalignantImmune Biology. SeminarsinHematology, 2014 51(3):206-18. (Impact factor: 3.357)

 

9.      Yiming Zhong *, Amy J. Johnson, John C. Byrd,and Jason A. Dubovsky*.  TargetingInterleukin-2-Inducible T-cell Kinase (ITK) in T-Cell Related Diseases.  Journal of Postdoctoral Research 2014 2(6):1-11. (*corresponding author).

 

10. Jennifer A. Woyach,Kelly Smucker, Lisa L. Smith, Arletta Lozanski, Yiming Zhong, Amy S. Ruppert, David Lucas, Katie Williams,Weiqiang Zhao, Laura Rassenti, EmanuelaGhia, Thomas J. Kipps, Rose Mantel,Jeffrey Jones, Joseph Flynn,Kami Maddocks, Susan O’Brien, RichardR. Furman, Danelle F. James,Fong Clow, Gerard Lozanski,Amy J. Johnson, John C.Byrd.  Prolonged Lymphocytosis During IbrutinibTherapy Is Associated With Distinct Molecular Characteristics and Does NotIndicate A Suboptimal Response To Therapy. Blood 2014 123(12):1810-7(Impact factor:9.775)

 

11. Yiming Zhong *,Ta-Ming Liu and Amy J. Johnson. A Breakthrough Therapy in RelapsedChronic Lymphocytic Leukemia: theCombination of Idelalisib and Rituximab.  Journal of Postdoctoral Research 2014 2 (3): 39-40. (*correspondingauthor).

 

12. Yiming Zhong * and Yuh-Ying Ye. Validated Critical Roles of Bruton’s TyrosineKinase (BTK) in Chronic Lymphocytic Leukemia (CLL). Journal of Postdoctoral Research 2014 2 (2):43-45 (*corresponding author)

 

13. Zhong Yand Byrd JC. IRF4-/-Vh11 mice: a novel mousemodel of CLL. Blood. 2013 122(16):2769-70. (Impactfactor: 9.775)

 

14. Dubovsky JA, Beckwith KA,Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frissora FW,Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA,Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ,Byrd JC. Ibrutinib isan irreversible molecular inhibitor of ITK drivinga Th1-selective pressure in T lymphocytes. Blood. 2013 122(15):2539-49. (Plenary Paper) (Impact factor:9.775)

 

15. Yiming Zhong and John C.Byrd. Genetic Evolution PromotesProgression and DrivesRelapse in CLL. The Hematologist. September 1, 2013

 

16. Zhong Yand Byrd JC. UGT2B17 as a diseaseaccelerator in CLL. Blood. 2013 121(7):1067-8.  (Impact factor:9.775)

 

17. Lapalombella R, Sun Q, WilliamsKatie, Jha S, Zhong Y,Goettl V, MahoneyE, Berglund C, Alicia F, Rajes M,Johnson AJ; Lucas DM, Mo X, DirkD, Vincent S, SharonS, Dilara M, Sharon S, Michael K, Yuh MC,Byrd JC. SelectiveInhibitors of NuclearExport (SINE) show that CRM1/XPO1 is a targetin Chronic Lymphocytic Leukemia.  Blood 2012 120(23):4621-34. (Impact factor:9.775)

 

18. Motiwala T, Zanesi N, Datta J, Roy S, Kutay H, Checovich AM, Kaou M, Zhong Y, Johnson AJ, Lucas DM, Heerema NA, Hagan J, Mo X, Jarjoura D, Byrd JC,Croce CM, Jacob ST. AP-1 elementsandTCL1 protein regulateexpression of the gene encodingprotein tyrosine phosphatase PTPROt in leukemia. Blood 2011 118(23):6132-40. (Impactfactor: 9.775)

 

19. Yiming Zhong, Brent Sullenbarger, Larry C. Lasky. Effect ofincreased HoxB4 on humanmegakaryocytic development.  Biochemical andBiophysical ResearchCommunications. 2010 398(3):377-382. (Impact factor: 2.406)

 

20. ZHONG Yiming, JIANG Guanghuai, CHEN Xuewei, XIA Zhihui, LI Xiaobing, ZHU Lihuang, ZHAI Wenxue. Identification and gene prediction of a 24 kb regioncontaining xa5, a recessive bacterial blight resistance gene in rice(Oryza sativa L.). CHINESE SCIENCEBULLETIN 2003 48(24): 2725-2729.  (Impact factor: 1.319)

Resume : Download
 
     
btm
 
 
top
 
 
 
 
 
btm

 
footer
 
 
home phone mail info@postdocjournal.com
 
twitter facebook social icon Social link You Tube sky
Click Here